← Browse by Condition
Medical Condition

chronic pulmonary aspergillosis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for chronic pulmonary aspergillosis sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 2
1
Top Sponsors
Mundipharma Research Limited 1 trial
Imperial College London 1 trial
Post Graduate Institute of Medical Education and Research, Chandigarh 1 trial
NCT06794554 Phase 2
Recruiting

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

Enrollment
60 pts
Location
Austria, Belgium, Fr...
Sponsor
Mundipharma Research Limited
View Trial →
NCT06885905
Recruiting

Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

Enrollment
100 pts
Location
United Kingdom
Sponsor
Imperial College London
View Trial →
NCT05444946
Recruiting

Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome

Enrollment
104 pts
Location
India
Sponsor
Post Graduate Institute of Med...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology